CoChat
Sign Up
Cited by 60

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The mutagenic impact of melphalan in multiple myeloma

Maura, Francesco, Weinhold, Niels, Diamond, Benjamin, Kazandjian, Dickran, Rasche, Leo, Morgan, Gareth, Landgren, Ola·2021·Leukemia
DOI 10.1038/s41375-021-01293-3
Open this paper in CoChat — free account

Abstract

The introduction of whole genome and exome sequencing partnered with advanced bioinformatic pipelines has allowed the comprehensive characterization of mutational processes (i.e., mutational signatures) in individual cancer patients. Studies focusing on multiple myeloma have defined several mutational processes, including a recently identified mutational signature (called "SBS-MM1") directly caused by exposure to high-dose melphalan (i.e., autologous stem cell transplant). High-dose melphalan exposure increases both the overall and nonsynonymous mutational burden detected between diagnosis and relapse by ~10-20%. Nevertheless, most of these mutations are acquired within the heterochromatin and late-replicating regions, rarely involving key myeloma driver genes. In this review, we summarize key studies that made this discovery possible, and we discuss potential clinical implications.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41375-021-01293-3

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 4 references

Research works printed but not linked: 31

  1. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55–65. · DOI
  2. Tacchetti P, Pantani L, Patriarca F, Petrucci MT, Zamagni E, Dozza L, et al. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematol. 2020;7:e861–e873. · DOI
  3. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006;135:158–64. · DOI
  4. Paiva B, Puig N, Cedena MT, Rosinol L, Cordon L, Vidriales MB, et al. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. J Clin Oncol. 2020;38:784–92. · DOI
  5. Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT, et al. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2020;38:1928–37. · DOI · Paper page
  6. Engelhardt M, Ihorst G, Landgren O, Pantic M, Reinhardt H, Waldschmidt J, et al. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. Haematologica. 2015;100:1340–9. · DOI
  7. Maclachlan K, Diamond B, Maura F, Hillengass J, Turesson I, Landgren CO, et al. Second malignancies in multiple myeloma; emerging patterns and future directions. Best Pr Res Clin Haematol. 2020;33:101144. · DOI
  8. Razavi P, Rand KA, Cozen W, Chanan-Khan A, Usmani S, Ailawadhi S. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J. 2013;3:e121. · DOI
  9. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. Myeloma Trialists’ Collaborative Group. J Clin Oncol. 1998;16:3832–42. · DOI
  10. Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456–e468. · DOI
  11. Gay F, Musto P, Rota Scalabrini D, Galli M, Belotti A, Zamagni E, et al. Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial. Blood. 2020;136:35–37. · DOI
  12. Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456–64. · DOI
  13. Goicoechea I, Puig N, Cedena MT, Burgos L, Cordon L, Vidriales MB, et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma. Blood. 2020;137:49–60. · DOI
  14. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94–101. · DOI · Paper page
  15. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21. · DOI · Paper page
  16. Maura F, Degasperi A, Nadeu F, Leongamornlert D, Davies H, Moore L, et al. A practical guide for mutational signature analysis in hematological malignancies. Nat Commun. 2019;10:2969. · DOI · Paper page
  17. Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E, et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia. 2017;32:1044–1048. · DOI
  18. Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128:1735–44. · DOI
  19. Bolli F, Maura M, Minvielle M, Gloznik D, Szalat R, Fullam A, et al. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018;9:3363. · DOI · Paper page
  20. Degasperi A, Amarante TD, Czarnecki J, Shooter S, Zou X, Glodzik D, et al. A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies. Nat Cancer. 2020;1:249–63. · DOI · Paper page
  21. Rustad EH, Nadeu F, Angelopoulos N, Ziccheddu B, Bolli N, Puente XS, et al. mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies. Commun Biol. 2021;4:424. · DOI
  22. Rustad EH, Yellapantula V, Leongamornlert D, Bolli N, Ledergor G, Nadeu F, et al. Timing the initiation of multiple myeloma. Nat Commun. 2020;11:1917. · DOI · Paper page
  23. Kucab JE, Zou X, Morganella S, Joel M, Nanda AS, Nagy E, et al. A Compendium of Mutational Signatures of Environmental Agents. Cell. 2019;177:821–36. · DOI · Paper page
  24. Landau HJ, Yellapantula V, Diamond BT, Rustad EH, Maclachlan KH, Gundem G, et al. Accelerated single cell seeding in relapsed multiple myeloma. Nat Commun. 2020;11:3617. · DOI
  25. Ziccheddu B, Biancon G, Bagnoli F, De Philippis C, Maura F, Rustad EH, et al. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Adv. 2020;4:830–44. · DOI
  26. Lee-Six H, Olafsson S, Ellis P, Osborne RJ, Sanders MA, Moore L, et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature. 2019;574:532–7. · DOI · Paper page
  27. Pich O, Cortes-Bullich A, Muiños F, Pratcorona M, Gonzalez-Perez A, Lopez-Bigas N. The evolution of hematopoietic cells under cancer therapy. bioRxiv. 2020. https://www.biorxiv.org/content/10.1101/2020.10.29.360230v1. · DOI
  28. Pich O, Muinos F, Lolkema MP, Steeghs N, Gonzalez-Perez A, Lopez-Bigas N. The mutational footprints of cancer therapies. Nat Genet. 2019;51:1732–40. · DOI · Paper page
  29. Samur MK, Roncador M, Aktas-Samur A, Fulciniti M, Bazarbachi AH, Szalat R, et al. High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma. Blood. 2020;136:4–5. · DOI
  30. Poos AM, Giesen N, Catalano C, Paramasivam N, Huebschmann D, John L, et al. Comprehensive Comparison of Early Relapse and End-Stage Relapsed Refractory Multiple Myeloma. Blood. 2020;136. · DOI
  31. Wuilleme S, Lok A, Robillard N, Dupuis P, Stocco V, Migne H, et al. Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma. Bone Marrow Transpl. 2016;51:1143–5. · DOI

Cited by

See all 60

Metadata

Authors
Maura, F., Weinhold, N., Diamond, B., Kazandjian, D., Rasche, L., Morgan, G., & Landgren, O.
Venue
Leukemia
Publisher
Springer Science and Business Media LLC
Published
2021-05-19
Volume
35
Issue
8
Pages
2145-2150
ISSN
  • 0887-6924
  • 1476-5551
DOI
10.1038/s41375-021-01293-3
Cited by
60
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The mutagenic impact of melphalan in multiple myeloma. https://app.cochat.ai/papers/10.1038/s41375-021-01293-3
The paper
Maura, F., Weinhold, N., Diamond, B., Kazandjian, D., Rasche, L., Morgan, G., & Landgren, O. (2021). The mutagenic impact of melphalan in multiple myeloma. Leukemia. https://doi.org/10.1038/s41375-021-01293-3